Dr. J. Leonard Lichtenfeld

CT
CT colonography and Medicare: Are we the enemy?
In this editorial opinion, Dr. Len Lichtenfeld, deputy chief medical officer for the American Cancer Society, outlines his concerns over an editorial in the New England Journal of Medicine praising the decision by the U.S. Centers for Medicare and Medicaid Services not to cover CT colonography -- as well as his objections to the CMS decision itself.
June 23, 2009
2009 06 23 14 37 33 976 Second Opinion Am
Page 1 of 1
Top Stories
Mammography Tech Woman Social
Digital X-Ray
Most DCIS sizes are either over- or underestimated on x-ray
More than two out of three ductal DCIS sizes are radiologically either over- or underestimated on x-ray imaging.
Post-Pluvicto SPECT/CT with axial fused images of sacrum and sagittal maximum intensity projection of one of the patients who complained of increasing pain in the sacral region (arrows) post therapy.
Nuclear Medicine
What side effects do patients report after Pluvicto therapy?
Suicide
Molecular Imaging
Brain SPECT offers insight into suicide risk
Minnie Cast Thumbnail (9)
Womens Imaging
Women's Imaging MinnieCast, Episode 10: To treat or not to treat DCIS?
Webinar: AI for CT & PET/CT Imaging
Sponsor Content
Webinar: AI for CT & PET/CT Imaging
More in Home
Most DCIS sizes are either over- or underestimated on x-ray
By Amerigo Allegretto
More than two out of three ductal DCIS sizes are radiologically either over- or underestimated on x-ray imaging.
June 5, 2026
Mammography Tech Woman Social
What side effects do patients report after Pluvicto therapy?
By Will Morton
Fatigue, pain flare, nausea, and urinary symptoms are among the most commonly reported immediate side effects of Pluvicto therapy.
June 5, 2026
Post-Pluvicto SPECT/CT with axial fused images of sacrum and sagittal maximum intensity projection of one of the patients who complained of increasing pain in the sacral region (arrows) post therapy.
Brain SPECT offers insight into suicide risk
By Kate Madden Yee
Study results show that a single resting-state scan yields individualized risk trajectories that identify high-risk patients.
June 5, 2026
Suicide
Women's Imaging MinnieCast, Episode 10: To treat or not to treat DCIS?
By Amerigo Allegretto
Lars Grimm, MD, discusses challenges in DCIS care and his work in the COMET study.
June 5, 2026
Minnie Cast Thumbnail (9)
PET reveals brain receptor deficits in schizophrenia
By Will Morton
The study confirms that deficits in M1 receptor are present in a subgroup of schizophrenia patients.
June 4, 2026
A Ibrain
MRI finds perfusion defects across a range of lung impairments
By Kate Madden Yee
Impaired lung function is associated with increased pulmonary perfusion defects detectable by a particular MRI technique.
June 4, 2026
Caption: Representative images show emphysema and functional lung maps derived by CT and PREFUL-MRI: (A–C) CT-derived emphysema images, (D–F) perfusion maps, (G–I) regional ventilation maps, (J–L) flow-volume loop correlation metric maps, (M–O) ventilation/perfusion combined parameter maps. (A, D, G, J, M) Images in a 63-year-old male with normal spirometry: FEV1%pred = 89.0%, FEV1/FVC = 0.73; emphysema percentage = 0.2%, QDP = 7%, VDPRVent = 2%, VDPFVL-CM = 1%. (B, E, H, K, N) Images in a 65-year-old female with PRISm + RP: FEV1%pred = 71.2%, FVC %pred = 76.8%, FEV1/FVC = 0.76; emphysema percentage = 4.7%, QDP = 10%, VD-PRVent = 18%, VDPFVL-CM = 6%. (C, F, I, L, O) Images in a 57-year-old male with AO: FEV1%pred = 56.8%, FEV1/FVC = 0.52; emphysema = 11.1%, QDP = 31%, VDPRVent = 33%, VDPFVL-CM = 41%. AO = airflow obstruction, FEV1 = forced expiratory volume in 1 second, FVC = forced vital capacity, FVL-CM = flow-volume loop correlation metric, %pred = percent predicted, PREFUL = phase-resolved function lung, PRISm = preserved ratio impaired spirometry, QDP = perfusion defect percentage, RVent = regional ventilation, VDP = ventilation defect percentage.
AI detects lung cancer nodules well but shows low specificity
By Kate Madden Yee
The finding suggests the models offer “a potential role as adjunctive tools for ruling out malignancy” rather than classifying it.
June 4, 2026
Am 2020 06 26 16 29 2945 Cancer Lung 400
Radiopharmaceutical manufacturers report uneven FDA inspections
By Liz Carey
RMTA lays out radiopharmaceutical regulatory and payment policy issues.
June 4, 2026
Lab Equipment Drug Manufacturing
AI-driven cardiac PET attenuation correction shows promise
By Kate Madden Yee
The algorithm could offer a “practical alternative in cardiac PET,” researchers noted.
June 3, 2026
Cardiac stress test imaging comparison showing DeepAC and CT-based attenuation correction scans for two patients with quantitative perfusion data.
Image-guided focal laser ablation effective for prostate cancer
By Amerigo Allegretto
MRI-directed, ultrasound-guided TPLA may be a promising technique to treat prostate cancer while avoiding radical therapies.
June 3, 2026
Preablation, postablation, and recurrence multiparametric MRI scans depict a 63-year-old man treated with transperineal focal laser ablation (TPLA) for localized prostate cancer. Clinical parameters included an initial prostate-specific antigen (PSA) level of 7.2 ng/mL, a Prostate Imaging Reporting and Data System (PI-RADS) grade 4 lesion (red circles) in the right apical peripheral zone, and a maximum tumor length of 5 mm. MRI-guided targeted biopsy confirmed a Gleason score 3+4 prostate cancer tumor. (A) Pre-ablation axial T2-weighted MRI scan and apparent diffusion coefficient (ADC) image shows the apical PI-RADS 4 lesion (circles). (B) Six-month post-ablation axial T2-weighted MRI scan and ADC image show cystic necrosis (arrows). There was no evidence of recurrence; the PSA level was 1.5 ng/mL. (C) One-year after ablation, the patient’s PSA level had increased to 4.3 ng/mL. Axial T2-weighted MRI scan and the ADC image shows a recurrent lesion (blue circles) in the right apical peripheral zone adjacent to the ablation scar. Targeted biopsy confirmed Gleason score 3+4 prostate cancer, which was classified as in-field recurrence of clinically significant prostate cancer and subsequently re-treated with TPLA. In summary, serial multiplanar MRI demonstrates treatment response after TPLA with post-ablation necrosis, followed by MRI-detected IFR confirmed with biopsy at 12-month follow-up. Multiparametric MRI was performed with a 3.0-T MRI scanner (Skyra; Siemens Healthineers) using T2-weighted, diffusion-weighted, and ADC sequences, with gadobenate dimeglumine contrast material administration (Bracco Diagnostics).
ASCO: With help from AI, interventions boost lung cancer screening
By Erik L. Ridley
Screening rate increased sharply over six years at the 17-hospital health system.
June 3, 2026
Asco Thumb
Philips Interactive Multimedia Reporting: Where Insight Meets Impact
By Philips Healthcare Informatics
Radiology is no longer just about what you see, it’s about how effectively you communicate it.
June 2, 2026
2260299 Philips 01 Aunt Minnie Leadgen Newsletter Banner 300x250 Static
Page 1 of 232
Next Page